Cord Blood America, Inc. (CBAI.OB), an umbilical cord stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide, has announced that revenues for the first nine months of 2007 totaled $5.698 million. This figure represents an increase of 121 percent when comparing these revenues to the value of $2.582 million that was reported during the same nine month period of 2006.
Consequently, revenue for the first three month period has also increased by a value of 44.7%. Cord Blood reported revenues of $1.654 million during this particular quarter, a positive change in when looking at the revenue figure of $1.143 million that was reported during the third quarter of 2006. Furthermore, the Company also posted a gross profit of $2.384 million during the first nine months of 2007 and also posted gross profit of $994,449 in the third quarter as well.
“The significant increase in revenue is partially due to the accretive acquisitions Cord Blood America has made, which increased the number of umbilical cord samples, and increased marketing efforts,” said Matthew Schissler, CEO. “We are posting results that should be recognized as significant achievements by the financial markets and by our investors”.
After this news was released, the share price for Cord Blood climbed over 18.75% throughout Tuesday’s trading hours. Investors, reacting favorably, exchanged an above average 1,000,000 shares throughout the day; contributing to the stocks upward momentum. Cord Blood’s upward trend should continue into the holiday season as investors have taken a keen eye on Cord Blood and their favorable future potential.
Cord Blood America, Inc. (CBAI.OB) Realizes 121% Increase in Revenues Tuesday, November 20th, 2007
Cord Blood America announced today that it has generated revenues of $5.698 million for the first nine months of 2007. This value is up 121% from revenues of $2.582 million for the same period last year.
Revenues for the quarter ended September 30, 2007 increased 44.7% to $1.654 million from revenues of $1.143 in the same period last year. The company also posted a gross profit of $2.384 million for the first nine months of 2007 and a gross profit of $994,449 for the third quarter of this year. Both of these values represent a significant increase compared to the gross profit of the first nine months of 2006 that totaled $527,070 and third quarter gross profit of $250,104.
Matthew Schissler, CEO of Cord Blood, stated, “The significant increase in revenue is partially due to the accretive acquisitions Cord Blood America has made, which increased the number of umbilical cord samples, and increased marketing efforts. We are posting results that should be recognized as significant achievements by the financial markets and by our investors.”
The CEO also pointed out that the loss from operations substantially decreased from $672,239 for the three months ended June 30, 2007 to only $67,082 for the three months ended September 30, 2007. He commented, “We said we want to run operationally profitable. This number is the biggest key indicator that the management is committed to this goal.”
"Please see the disclaimers on the QualityStocks.net website."
